News

Video

Triple Combination Therapies in RCC: Clinical Trial Insights

Author(s):

Ulka Vaishampayan, MD,Alan Tan, MD

Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.

Related Videos
David A. Braun, MD, PhD
Bradley McGregor, MD,
Naval G. Daver, MD,
Ami Umesh Badami, MD, medical oncologist, Endeavor Health Medical Group
Thomas Westbrook, MD, assistant professor, Department of Internal Medicine, Rush University
Related Content
Bradley McGregor, MD
January 15th 2025

Nivolumab Plus Ipilimumab May Offer Efficacious Therapeutic Approach in Rare GU Cancers

Jaffer A. Ajani, MD, GI medical oncologist, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
November 14th 2024

FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma

Yousef Zakharia, MD
January 14th 2025

Selecting Checkpoint Inhibitor–Based Regimens in Clear Cell RCC Requires Several Considerations

Oncology Unplugged
November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

Toni Choueiri, MD
January 8th 2025

TiNivo-2 Data Underscore Challenges With ICI Retreatment in Advanced RCC

Kelly K. Hunt, MD, FACS, FSSO, of MD Anderson Cancer Center
January 3rd 2025

One Surgeon’s Spirit and Brilliance Lift a Whole Community